LLY
Eli Lilly and Company · NYSE
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website lilly.com
- Employees(FY) 39000
- ISIN US5324571083
Performance
-0.04%
1W
+3.29%
1M
-1.38%
3M
+31.23%
6M
+32.54%
YTD
+77.3%
1Y
Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Investment Analysis Report: Eli Lilly and Company (LLY)
Overview:
Eli Lilly and Company (LLY) is a major player in the pharmaceutical industry with a market capitalization of $731.19 billion. The company operates in the Health Technology sector and specializes in Pharmaceuticals. In this report, we will conduct a detailed analysis of LLY's finan...
Technical Analysis of LLY 2024-05-10
Overview:
In analyzing the technical indicators for LLY over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed decis...
Recent News & Updates
- 2024-05-16 01:09
- 2024-05-16 00:03
- 2024-05-15 21:53
- 2024-05-15 20:18
- 2024-05-15 19:55
- 2024-05-15 19:28
Dow Jones Futures: Dow, S&P 500, Nasdaq Hit Highs, Nvidia Leads 12 New Buys; What To Do Now(Investor's Business Daily)
- 2024-05-15 19:15
- 2024-05-15 18:45
- 2024-05-15 18:15
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade(Investorplace)
- 2024-05-15 12:12
- 2024-05-15 11:36
- 2024-05-15 10:49
- 2024-05-15 09:53
- 2024-05-15 08:00
- 2024-05-15 05:44
- 2024-05-15 04:22
Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs(Yahoo Finance)
- 2024-05-14 20:59
Jim Cramer and Ken Fisher Love These 10 Stocks(Insidermonkey)
- 2024-05-14 20:00
- 2024-05-14 17:46
- 2024-05-14 17:00
- 2024-05-14 09:53
- 2024-05-14 08:15
- 2024-05-14 07:30
Is Eli Lilly's Latest Deal a Gamechanger?(Motley Fool)
- 2024-05-14 06:53
Analyst Report: Lilly(Eli) & Co(Argus Research)
- 2024-05-14 06:38
Market Digest: NDAQ, GOLD, ADTN, AJG, EMR, HLF, LLY, JCI, CHTR(Argus Research)
- 2024-05-14 06:30
- 2024-05-14 04:22
- 2024-05-13 19:52
- 2024-05-13 19:30
- 2024-05-13 18:30
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene(Investorplace)